Entire COX-2 Class Is TARGET Of Critical Lancet Editorial
This article was originally published in The Pink Sheet Daily
Executive Summary
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.
You may also be interested in...
FDA To Hold COX-2 Advisory Committee In Early 2005, Woodcock Says
The agency will have to make a trade-off between getting products on the market and determining their cardiovascular safety profile. Merck believes placebo-controlled trials in osteoarthritis patients should not be longer than four months due to ethical concerns.
FDA To Hold COX-2 Advisory Committee In Early 2005, Woodcock Says
The agency will have to make a trade-off between getting products on the market and determining their cardiovascular safety profile. Merck believes placebo-controlled trials in osteoarthritis patients should not be longer than four months due to ethical concerns.
Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis
The study found a lower risk of gastrointestinal side effects for Prexige compared to ibuprofen and naproxen, but the incidence of serious liver abnormalities was higher for the COX-2 than for the NSAIDs.